Muscle revival: mitochondrial transplants for aging

If your age is associated with your strength, you might be able to become younger by injecting mitochondria into your muscles. At least these are some recent findings of experiments on aging mice model. Read Hot Science below.

Longevity industry is at an inflection point and it is ripe for both mission-oriented investors and investors who are looking for the next Apple. Read about profound opinions of a  life extension investor and visionary, Laura Deming, in Hot Investments below.

‍

Hot Science

Some of the common age-related conditions, skeletal muscles deterioration and frailty are often associated with one of the cellular hallmarks of aging, mitochondrial dysfunction. Mitochondria, the "powerhouses of cells," are crucial for cell energy production. Recent study addressed  mitochondrial transplantation on aged mice to treat these conditions. This innovative approach involves directly injecting mitochondria into leg muscles, yielding substantial increases in muscle energy and performance. This technique promises to revitalize muscle strength and stamina in older populations. This study provides initial evidence showing how mitochondrial transplantation can promote skeletal muscle bioenergetics in an aging rodent model.

At Immorta Bio, we are developing cutting-edge technologies aimed at rejuvenation of individual's cells to a younger state, that are specifically enhancing mitochondrial health. Our approach in precision and personalized medicine is focused on longevity therapeutics with the proposed goal to drastically increase healthy lifespans by addressing aging at the cellular level.

‍

Hot Investments

Venture capitalist, Laura Deming, is all over the news, giving interviews and writing about life extension. She is definitely a mission-oriented investor. In her website letter she makes some profound predictions about the longevity industry. She expects that the next decade will produce some dominant longevity therapeutics players with Billions of Dollars valuations. These players will be solving not only the age-related diseases, but the aging itself.  

Immorta Bio, as a mission-oriented entrepreneurs-based longevity player, is well positioned to prove Laura predictions to be true. After all we are absolutely focused on Treating Diseases of Aging and Treating Aging as Disease™.

‍

Longevity Shorts

• Humanaut Health Secures $8.7M Seed Round to Bring Longevity Healthcare to Local Cities Across America.

• Immorta Bio makes a new step in senotherapeutics technologies by filing a provisional patent “Senescent Cell Targeting T Cell Responses by Ex Vivo Generated Antigen Presenting Cells”. It specifically presents experimental data on treating lung cancer.

• A placebo-controlled Phase 1/2 trial conducted recently in East Shanghai has found that administering umbilical cord-derived mesenchymal stem cells reduce frailty in older people.
  

‍

Term of the Day

Senescent Cells: The process of growing old in biology, senescence, is a process by which a cell ages and permanently stops dividing but does not die. Over time, large numbers of old (or senescent) cells can build up in tissues throughout the body causing chronic inflammation that can potentially lead to the onset of diseases of aging.

‍

Boris Reznik, PhD
Chairman